SGS continues to invest in bioanalytical testing to increase efficiency and regulatory compliance at its Poitiers, France, laboratory
The investment will enable higher throughput of samples, and electronic data capture to ensure integrity of information in regulatory submission and acceptances.
SGS has fully installed and validated an Immune Response Module (IRM) as part of its Watson laboratory information management system (LIMS), at its facility in Poitiers, France. The investment will enable higher throughput of samples, and electronic data capture to ensure integrity of information in regulatory submission and acceptances.
The investment in the IRM is the latest strategic step for the company in its key business area of large molecule bioanalysis. The module allows for faster immunogenicity data processing and easier consolidation of sample data, increasing the efficiency in terms of time and cost for clients. The integration of the module into the existing LIMS infrastructure means bioanalytical studies can be managed by one single tool, and clients’ immunogenicity data can be stored and processed within a secure environment.
The new module has been fully validated by SGS and can be used for GCP and GLP compliant studies.
“For our clients, this investment will reduce the time spent processing complex, bioanalytical data, and also ensure that any regulatory submission based upon results and data generated by SGS will stand up to scrutiny,” commented Alain Renoux, Laboratory Director of SGS Life Sciences Poitiers. “As a company, we are seeing much greater demand for bioanalytical testing as this field of research widens, and SGS continues to invest in areas that benefit our clients’ long term goals.”
With 20 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance